Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-01-18
Target enrollment:
Participant gender:
Summary
RATIONALE: Everolimus may stop the growth of tumor cells by blocking blood flow to the tumor.
PURPOSE: This randomized phase II trial is studying two different schedules of everolimus to
see how well they work in treating patients with recurrent or metastatic breast cancer.